The Bombay High Court set aside a stop-sale order issued by the Maharashtra Food and Drug Administration against Cadila Pharmaceuticals Ltd. on Tuesday [1, 2].
The ruling limits the ability of state regulators to halt the distribution of medicine without a judicious process, ensuring that pharmaceutical supplies are not disrupted by excessive administrative actions.
Acting Chief Justice R.V. Ghuge and Justice Gautam Ankhad presided over the bench that delivered the reprimand [1, 2]. The court said the regulator's approach was like using a "sword to kill a mosquito" [2].
During the proceedings, the bench criticized the FDA for what it characterized as a "shoot-first" mentality. Acting Chief Justice R.V. Ghuge said, "Shooting first and asking questions later is a rule of the Wild West that does not apply in law" [1].
The court found that the FDA had not exercised its authority responsibly. The bench said that the powers of the regulator must be exercised judiciously rather than displayed [1].
By granting relief to Cadila Pharmaceuticals, the court effectively nullified the order that had previously blocked the sale of several of the company's medicines [1, 2]. The court said the FDA must ensure its future regulatory actions are proportional to the issues they seek to address [1].
“"Shooting first and asking questions later is a rule of the Wild West that does not apply in law."”
This ruling establishes a judicial check on the Maharashtra FDA's discretionary powers, signaling that the court will not tolerate arbitrary stop-sale orders that lack proportional evidence. It reinforces the legal requirement for regulatory bodies to follow due process before interrupting the commercial availability of healthcare products.
